Laura Francis Sells 93,475 Shares of SiBone (NASDAQ:SIBN) Stock

SiBone (NASDAQ:SIBN) CEO Laura Francis sold 93,475 shares of the business’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $15.32, for a total value of $1,432,037.00. Following the completion of the transaction, the chief executive officer directly owned 544,369 shares of the company’s stock, valued at approximately $8,339,733.08. This trade represents a 14.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

SiBone Stock Performance

Shares of SIBN stock opened at $15.47 on Friday. The company has a 50 day moving average price of $17.90 and a 200-day moving average price of $16.85. SiBone has a 52 week low of $12.49 and a 52 week high of $21.89. The firm has a market capitalization of $671.24 million, a PE ratio of -30.33 and a beta of 0.69. The company has a quick ratio of 6.62, a current ratio of 7.97 and a debt-to-equity ratio of 0.21.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of SIBN. Invesco Ltd. increased its stake in SiBone by 18.5% in the 4th quarter. Invesco Ltd. now owns 55,715 shares of the company’s stock worth $1,099,000 after buying an additional 8,706 shares in the last quarter. Susquehanna Portfolio Strategies LLC grew its position in shares of SiBone by 579.2% during the fourth quarter. Susquehanna Portfolio Strategies LLC now owns 105,365 shares of the company’s stock worth $2,078,000 after purchasing an additional 89,851 shares in the last quarter. Tudor Investment Corp ET AL raised its stake in SiBone by 0.6% during the 4th quarter. Tudor Investment Corp ET AL now owns 259,589 shares of the company’s stock valued at $5,119,000 after purchasing an additional 1,557 shares during the period. Man Group plc purchased a new position in SiBone in the 4th quarter worth approximately $965,000. Finally, Inspire Investing LLC bought a new position in SiBone in the 4th quarter worth approximately $1,246,000. Institutional investors own 98.11% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently commented on SIBN shares. Morgan Stanley lifted their price objective on SiBone from $20.00 to $23.00 and gave the stock an “overweight” rating in a report on Tuesday, December 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of SiBone in a research report on Monday, December 29th. Canaccord Genuity Group increased their price objective on shares of SiBone from $26.00 to $27.00 and gave the stock a “buy” rating in a research note on Wednesday, December 17th. Truist Financial boosted their target price on shares of SiBone from $21.00 to $23.00 and gave the company a “buy” rating in a research report on Thursday, December 18th. Finally, Needham & Company LLC increased their price target on shares of SiBone from $24.00 to $27.00 and gave the stock a “buy” rating in a research report on Tuesday, December 16th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $24.33.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.